Videos

Nirogacestat Demonstrates Potential as Standard of Care for Progressing Desmoid Tumors Requiring Systemic Therapy

09/13/2022

Bernd Kasper, MD, PhD, Mannheim Cancer Center, Germany, discusses findings from the phase 3 DeFi trial, in which nirogacestat demonstrated a 71% reduction in the risk of disease progression or death vs placebo in patients with progressing desmoid tumors. This trial marks the first positive phase 3 results for a gamma secretase inhibitor in any indication.

Dr Kasper presented these findings at the 2022 European Society for Medical Oncology (ESMO) Congress.

Source:

Kasper B, Ratan R, Alcindor T, et al. DeFi: A phase III, randomized controlled trial of nirogacestat versus placebo for progressing desmoid tumors (DT). Presented at: ESMO Congress; September 9-13, 2022. Paris, France and virtual. Abstract LBA2.

Recent News

News

First-Line Pembrolizumab Plus Chemotherapy Showed Promise Among Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

07/26/2024

Stephanie Holland ;

According to results from the KEYNOTE-B10 trial, first-line pembrolizumab plus carboplatin and paclitaxel showed promising antitumor activity with manageable safety among patients with recurrent or metastatic head and neck squamous cell...

According to results from the...

07/26/2024

Oncology

News

Potential for Shorter Monitoring Period for Patients With R/R MM Following CAR-T Therapy

07/26/2024

Amber Denham ;

A shorter monitoring period may be reasonable for patients with relapsed/refractory multiple myeloma who underwent CAR-T therapy following results that suggest a low risk of cytokine release syndrome and immune effector cell-associated...

A shorter monitoring period may...

07/26/2024

Oncology

News

Utilizing T-Cell Assays in Diagnosing Familial Hemophagocytic Lymphohistiocytosis and Defects in Lymphocyte Exocytosis

07/25/2024

Amber Denham ;

According to a prospective analysis, a combined use of TCR-triggered T-cell and FcR-triggered NK-cell exocytosis assays demonstrated efficacy in diagnosing familial hemophagocytic lymphohistiocytosis and defects in lymphocyte exocytosis.

According to a prospective...

07/25/2024

Oncology

News

SHR-A1811 Showed Promise Among Patients With HER2-Expressing Solid Tumors

07/25/2024

Stephanie Holland ;

According to results from a first-in-human, phase 1 study, SHR-A1811 demonstrated promising antitumor activity with acceptable safety and tolerability among heavily pretreated patients with HER2-expressing or mutated advanced solid tumors.

According to results from a...

07/25/2024

Oncology

News

Brentuximab Vedotin and Ibrutinib Combination Fails to Provide Safety Among Patients With R/R Hodgkin Lymphoma

07/23/2024

Amber Denham ;

According to results from a phase 2 trial, brentuximab vedotin and ibrutinib therapy demonstrated activity among patients with R/R Hodgkin lymphoma, however the combination cannot be recommended for future therapeutic development due to...

According to results from a...

07/23/2024

Oncology

News

Combined Low-Dose Ruxolitinib and Emapalumab Treatment Demonstrates Efficacy for Patients With Hemophagocytic Lymphohistiocytosis

07/23/2024

Gina Tomaine ;

The combination of low-dose ruxolitinib and anti-interferon-gamma antibody emapalumab demonstrated efficacy and safety for treating patients with hemophagocytic lymphohistiocytosis, according to a retrospective analysis.

The combination of low-dose...

07/23/2024

Oncology

News

Analyzing Real-World Outcomes of Emapalumab Treatment for Patients With Primary Hemophagocytic Lymphohistiocytosis

07/23/2024

Gina Tomaine ;

According to retrospective study REAL-HLH, the real-world clinical efficacy, patterns, and survival outcomes of emapalumab treatment among patients with primary hemophagocytic lymphohistiocytosis were consistent with the results a pivotal...

According to retrospective study...

07/23/2024

Oncology

News

Maintenance Selinexor Showed Promise for Patients With Advanced or First-Line Recurrent TP53 Wild-Type Endometrial Cancer

07/23/2024

Stephanie Holland ;

Subgroup analysis results from the phase 3 SIENDO study found selinexor demonstrated promising efficacy and safety among patients with advanced or first-line recurrent TP53 wild-type endometrial cancer.

Subgroup analysis results from...

07/23/2024

Oncology

News

Dostarlimab Plus Chemotherapy as New Standard of Care for Patients With Primary Advanced or Recurrent Endometrial Cancer

07/22/2024

Stephanie Holland ;

Second interim analysis results from the phase 3 RUBY trial demonstrated that the addition of dostarlimab to chemotherapy improved overall survival among patients with primary advanced or recurrent endometrial cancer.

Second interim analysis results...

07/22/2024

Oncology

News

First-Line Amivantamab Plus Lazertinib Superior to Osimertinib Among Patients With Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

07/18/2024

Stephanie Holland ;

Results from the phase 3 MARIPOSA study found that first-line amivantamab plus lazertinib demonstrated superior efficacy compared to osimertinib among patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.

Results from the phase 3...

07/18/2024

Oncology